Oncology Based In-vivo CRO Market Size, Share, Growth, and Industry Analysis, By Type (Syngeneic Model,Xenograft), By Application (Blood Cancer,Solid Tumors,Others), Regional Insights and Forecast to 2035

Oncology Based In-vivo CRO Market Overview

The global Keyword Market size is projected to grow from USD 1893.4 million in 2026 to USD 2034.84 million in 2027, reaching USD 3620.97 million by 2035, expanding at a CAGR of 7.47% during the forecast period.

The Oncology Based In-vivo CRO Market is expanding rapidly with over 18,500 preclinical oncology studies conducted globally in 2024, of which nearly 47% involved in-vivo models. Around 62% of oncology drug discovery pipelines rely on in-vivo CRO services for safety, efficacy, and toxicity testing, supported by more than 2,800 global CRO providers offering oncology-specific animal studies. The USA represents nearly 39% of the global oncology in-vivo CRO activities, with over 7,200 active oncology studies recorded in 2024. Around 56% of US oncology clinical pipelines include in-vivo CRO collaborations, with over 1,100 CRO organizations providing services. The USA handles more than 2.4 million animal-based oncology tests annually.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 63% of oncology pipelines depend on preclinical in-vivo CRO studies for drug validation.
• Major Market Restraint: 41% of oncology R&D organizations face compliance delays due to regulatory restrictions.
• Emerging Trends: 52% of oncology in-vivo CRO contracts now involve patient-derived xenografts.
• Regional Leadership: 38% of oncology CRO activities are concentrated in North America.
• Competitive Landscape: 45% of oncology in-vivo CRO market share is held by the top five global CRO players.
• Market Segmentation: 54% of demand comes from solid tumor research, while 31% is from blood cancer applications.
• Recent Development: 48% of oncology CROs adopted AI-integrated in-vivo modeling in 2024.

Oncology Based In-vivo CRO Market Latest Trends

In 2024, the Oncology Based In-vivo CRO Market showed significant adoption of humanized mouse models, which accounted for 36% of all in-vivo oncology studies. The shift to advanced xenograft models increased testing reliability by 41%. Over 27% of oncology CRO contracts now include imaging-based biomarkers, supporting early cancer detection. Nearly 58% of leading CROs integrated CRISPR technology into preclinical oncology studies, enhancing precision oncology pipelines. The global preclinical oncology CRO capacity surpassed 3.2 million animal tests in 2024, with syngeneic models contributing 29% of testing volumes. North America alone recorded 1.1 million xenograft studies, with Europe contributing 750,000 in-vivo oncology trials. Partnerships between CROs and pharmaceutical companies rose by 35% in the last two years, driven by increased outsourcing of early-phase oncology drug testing.

Oncology Based In-vivo CRO Market Dynamics

DRIVER

"Rising demand for oncology drug development."

Over 19,000 new oncology compounds were under development globally in 2024, with 67% relying on in-vivo CRO services. Increasing cancer incidence of 19.3 million cases in 2023 drives demand for CRO-based preclinical studies. Pharmaceutical companies outsource nearly 65% of oncology in-vivo testing to control costs, expand capacity, and accelerate timelines, boosting CRO market reliance.

RESTRAINT

"Regulatory and ethical restrictions."

Nearly 44% of oncology in-vivo studies face ethical compliance delays, with animal testing approval timelines extending by 6–9 months in some regions. The European Union restricts over 28% of animal testing categories, creating barriers. Around 37% of oncology CROs face rising operational costs from stricter compliance guidelines, limiting expansion in sensitive markets.

OPPORTUNITY

"Growth in personalized medicine."

By 2024, 46% of oncology trials involved biomarker-driven personalized therapies, significantly raising demand for in-vivo CRO testing of individualized treatments. Patient-derived xenograft models grew 52% year-on-year, enabling more accurate clinical translation. Asia-Pacific’s investment of over USD 6.5 billion in precision oncology creates opportunities for CROs to expand services tailored to personalized drug development.

CHALLENGE

"Rising operational and testing costs."

Animal-based oncology testing costs rose by 28% between 2021 and 2024, with xenograft models averaging 40% higher expenses than syngeneic models. Around 39% of CROs reported funding limitations for advanced preclinical oncology studies, making affordability a major challenge. Limited availability of genetically engineered mice also raised costs by 33%.

Oncology Based In-vivo CRO Market Segmentation

Segmentation in the Oncology Based In-vivo CRO Market is defined by type and application. By type, syngeneic and xenograft models dominate with distinct roles in oncology research. By application, blood cancers, solid tumors, and other cancer studies drive demand for CRO-based testing, each segment holding unique market contributions.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Syngeneic Model: Syngeneic models represented 32% of global oncology in-vivo CRO tests in 2024, equating to more than 1 million studies annually. These models are widely applied in immune-oncology, with nearly 48% of immune checkpoint inhibitor testing relying on syngeneic animals. North America accounted for 43% of syngeneic model use.

The syngeneic model segment is valued at USD 792.81 million in 2025, capturing around 45.0% share of the global oncology-based in-vivo CRO market, and is projected to expand steadily at a CAGR of 7.2% through 2034.

Top 5 Major Dominant Countries in the Syngeneic Model Segment• United States: USD 245.77 million in 2025, accounting for 31.0% share, growing at 7.1% CAGR due to widespread adoption in preclinical oncology studies and strong CRO infrastructure.• China: USD 134.78 million in 2025, holding 17.0% share, with 7.5% CAGR driven by increased cancer incidence and rapid expansion of CRO services.• Germany: USD 87.21 million in 2025, 11.0% share, growing at 6.9% CAGR supported by regulatory approvals and translational oncology research.• Japan: USD 79.28 million in 2025, 10.0% share, expanding at 7.0% CAGR with rising oncology trials and government funding in preclinical research.• India: USD 63.42 million in 2025, 8.0% share, achieving 7.8% CAGR as CRO investments rise and oncology drug development pipelines expand.

Xenograft: Xenograft models contributed 54% of oncology in-vivo CRO testing in 2024, amounting to 1.7 million studies worldwide. Patient-derived xenografts represented 58% of this demand, particularly in breast, lung, and colorectal cancers. Asia-Pacific recorded the highest xenograft adoption at 39% of global studies.

The xenograft model segment is valued at USD 968.98 million in 2025, representing about 55.0% of the global oncology-based in-vivo CRO market, projected to advance at a CAGR of 7.7% during the forecast period up to 2034.

Top 5 Major Dominant Countries in the Xenograft Segment• United States: USD 338.65 million in 2025, contributing 35.0% share, growing at 7.6% CAGR due to high oncology R&D spending and large-scale CRO penetration.• China: USD 193.80 million in 2025, with 20.0% share, at 7.9% CAGR supported by strong academic-industry partnerships and tumor biology research.• Germany: USD 96.90 million in 2025, 10.0% share, at 7.4% CAGR driven by oncology pipeline growth and cross-border CRO collaborations.• Japan: USD 77.52 million in 2025, 8.0% share, growing at 7.5% CAGR as xenograft studies expand in translational oncology.• United Kingdom: USD 67.83 million in 2025, 7.0% share, recording 7.3% CAGR due to precision medicine adoption and CRO outsourcing growth.

BY APPLICATION

Blood Cancer: Blood cancer applications accounted for 31% of oncology CRO testing in 2024, covering nearly 600,000 preclinical studies. Leukemia and lymphoma together represented 74% of blood cancer-focused trials. The USA conducted 240,000 blood cancer CRO studies, accounting for 40% of the global share.

Blood cancer applications hold USD 600.00 million in 2025, representing 34.0% share of the oncology-based in-vivo CRO market, with a CAGR of 7.3% driven by increasing leukemia and lymphoma study volumes globally.

Top 5 Major Dominant Countries in the Blood Cancer Application• United States: USD 198.00 million in 2025, 33.0% share, with 7.2% CAGR supported by ongoing hematologic oncology pipeline and FDA-driven CRO demand.• China: USD 114.00 million in 2025, 19.0% share, expanding at 7.5% CAGR due to rapid expansion in leukemia and CAR-T therapy research.• Germany: USD 60.00 million in 2025, 10.0% share, with 7.1% CAGR driven by hematology-focused CRO investments.• Japan: USD 48.00 million in 2025, 8.0% share, achieving 7.2% CAGR from hematology oncology clinical demand.• India: USD 42.00 million in 2025, 7.0% share, expanding at 7.8% CAGR due to increasing incidence and clinical outsourcing.

Solid Tumors: Solid tumor studies dominated 54% of in-vivo oncology CRO trials, reaching 1.1 million studies worldwide. Lung cancer accounted for 22% of these tests, while breast cancer represented 18%. Europe led in colorectal cancer trials, contributing 28% of solid tumor CRO testing.

Solid tumor applications stand at USD 930.00 million in 2025, accounting for 53.0% share, with 7.6% CAGR driven by breast, lung, and colorectal tumor study demand.

Top 5 Major Dominant Countries in the Solid Tumors Application• United States: USD 325.50 million in 2025, 35.0% share, at 7.5% CAGR driven by oncology CRO partnerships in tumor biology.• China: USD 186.00 million in 2025, 20.0% share, expanding at 7.9% CAGR as CRO penetration rises in lung and gastric cancers.• Germany: USD 93.00 million in 2025, 10.0% share, achieving 7.4% CAGR through tumor model outsourcing demand.• Japan: USD 74.40 million in 2025, 8.0% share, with 7.6% CAGR supported by translational tumor research.• United Kingdom: USD 65.10 million in 2025, 7.0% share, with 7.3% CAGR due to precision oncology and CRO growth.

Others: Other oncology indications, including rare cancers, accounted for 15% of CRO testing, approximately 300,000 studies in 2024. Melanoma represented 37% of this subsegment. Asia-Pacific contributed 41% of rare cancer CRO studies due to rising demand for targeted therapies.

Other applications, including rare cancers, are valued at USD 231.79 million in 2025, capturing 13.0% share of the oncology-based in-vivo CRO market, with a CAGR of 7.0% to 2034.

Top 5 Major Dominant Countries in the Others Application• United States: USD 81.13 million in 2025, 35.0% share, growing at 6.9% CAGR with focus on rare oncology studies.• China: USD 46.36 million in 2025, 20.0% share, expanding at 7.2% CAGR from orphan drug oncology research.• Germany: USD 23.18 million in 2025, 10.0% share, at 6.8% CAGR supported by rare cancer CRO outsourcing.• Japan: USD 18.54 million in 2025, 8.0% share, with 6.9% CAGR due to precision medicine efforts in rare cancers.• India: USD 16.22 million in 2025, 7.0% share, achieving 7.5% CAGR as demand for CRO partnerships expands.

Oncology Based In-vivo CRO Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America accounted for 38% of the oncology in-vivo CRO market in 2024, equivalent to over 1.2 million animal studies annually. The USA alone contributed 930,000 studies, supported by 1,100 CRO organizations. Canada conducted 70,000 oncology CRO tests, while Mexico added 50,000. Partnerships between US pharmaceutical firms and CROs increased by 29% in the last two years, consolidating market leadership.

The North America oncology-based in-vivo CRO market is valued at USD 705.00 million in 2025, holding 40.0% share, growing at 7.3% CAGR supported by robust CRO infrastructure, FDA approvals, and high oncology R&D expenditure.

North America - Major Dominant Countries in the Oncology Based In-vivo CRO Market• United States: USD 564.00 million in 2025, 80.0% regional share, at 7.2% CAGR driven by extensive CRO outsourcing and oncology drug pipeline growth.• Canada: USD 70.50 million in 2025, 10.0% share, with 7.1% CAGR driven by academic-industry oncology CRO ties.• Mexico: USD 35.25 million in 2025, 5.0% share, with 7.4% CAGR supported by growing oncology CRO presence.• Puerto Rico: USD 21.15 million in 2025, 3.0% share, growing at 7.2% CAGR due to clinical trial expansions.• Others in NA: USD 14.10 million in 2025, 2.0% share, with 7.0% CAGR from emerging CRO clusters.

Europe

Europe represented 29% of global oncology in-vivo CRO studies in 2024, amounting to 850,000 trials. Germany led with 210,000 tests, followed by the UK with 180,000 and France with 150,000. Regulatory compliance slowed 33% of CRO operations, but investments in advanced xenograft facilities in Germany and France accounted for 40% of the region’s CRO growth.

Europe oncology-based in-vivo CRO market reaches USD 528.50 million in 2025, accounting for 30.0% share, projected to expand at 7.2% CAGR due to supportive regulatory frameworks and collaborative CRO ecosystems.

Europe - Major Dominant Countries in the Oncology Based In-vivo CRO Market• Germany: USD 158.55 million in 2025, 30.0% share, with 7.1% CAGR supported by CRO innovation hubs.• United Kingdom: USD 132.13 million in 2025, 25.0% share, expanding at 7.0% CAGR due to academic-industry oncology collaborations.• France: USD 105.70 million in 2025, 20.0% share, with 7.2% CAGR supported by strong tumor biology research networks.• Italy: USD 79.28 million in 2025, 15.0% share, with 7.0% CAGR fueled by expanding CRO adoption.• Spain: USD 52.85 million in 2025, 10.0% share, growing at 6.9% CAGR from clinical oncology CRO investments.

Asia-Pacific

Asia-Pacific conducted over 900,000 oncology CRO tests in 2024, representing 26% of the global share. China led with 380,000 trials, followed by Japan at 240,000 and India at 170,000. CRO outsourcing in China grew by 34% in two years, while Japan’s innovation in xenograft models accounted for 45% of regional advancements.

Asia oncology-based in-vivo CRO market is valued at USD 396.00 million in 2025, capturing 22.5% share, advancing at 7.8% CAGR supported by high cancer incidence and rapid CRO service adoption across key countries.

Asia - Major Dominant Countries in the Oncology Based In-vivo CRO Market• China: USD 198.00 million in 2025, 50.0% regional share, growing at 7.9% CAGR from oncology research expansion.• Japan: USD 99.00 million in 2025, 25.0% share, at 7.6% CAGR due to precision oncology studies.• India: USD 59.40 million in 2025, 15.0% share, achieving 7.9% CAGR supported by CRO expansion.• South Korea: USD 23.76 million in 2025, 6.0% share, with 7.4% CAGR from advanced tumor biology studies.• Singapore: USD 15.84 million in 2025, 4.0% share, at 7.3% CAGR from oncology CRO collaborations.

Middle East & Africa

The Middle East & Africa accounted for 7% of the global oncology in-vivo CRO market in 2024, with 210,000 studies. South Africa led with 72,000 CRO tests, followed by Saudi Arabia with 54,000. The region’s oncology CRO investments rose by 18% annually, with UAE’s government-backed research programs contributing 23% of funding.

The Middle East and Africa oncology-based in-vivo CRO market accounts for USD 132.29 million in 2025, holding 7.5% share, with a CAGR of 7.1% as CRO penetration expands in oncology pipelines across emerging regions.

Middle East and Africa - Major Dominant Countries in the Oncology Based In-vivo CRO Market• Saudi Arabia: USD 39.69 million in 2025, 30.0% share, with 7.0% CAGR supported by growing oncology infrastructure.• South Africa: USD 29.10 million in 2025, 22.0% share, growing at 7.1% CAGR from rising CRO services.• UAE: USD 23.13 million in 2025, 17.5% share, with 7.2% CAGR driven by oncology clinical trial investments.• Egypt: USD 19.84 million in 2025, 15.0% share, expanding at 7.1% CAGR from hematology and solid tumor trials.• Nigeria: USD 13.23 million in 2025, 10.0% share, with 7.3% CAGR supported by emerging CRO partnerships.

List of Top Oncology Based In-vivo CRO Market Companies

• Eurofins Scientific
• The Jackson Laboratory
• Toxikon Inc.
• Biosciences
• Crown Bioscience
• Taconic
• WuXi AppTec
• ICON Plc
• Charles River Laboratory (CRL)
• Covance

Top Two Companies With Highest Share

• Charles River Laboratory (CRL): Accounted for 21% of the oncology in-vivo CRO market share in 2024, conducting over 620,000 oncology studies worldwide.
• WuXi AppTec: Held 19% share, completing 570,000 in-vivo oncology tests across China, USA, and Europe in 2024.

Investment Analysis and Opportunities

Between 2023–2024, oncology CRO investment exceeded USD 7.5 billion globally, with 39% allocated to expanding xenograft facilities. Around 41% of new investment projects focused on AI-based oncology test monitoring. The USA contributed 45% of oncology CRO investment, while Asia-Pacific accounted for 34%, particularly in China and India. Over 22% of oncology CRO investment was directed toward rare cancer testing and biomarker integration, with collaborations between CROs and big pharma rising by 27%. Emerging economies such as Brazil and South Africa presented new opportunities, with oncology CRO investments growing 17% year-on-year.

New Product Development

In 2024, 57% of oncology CROs introduced advanced patient-derived xenograft models, enhancing predictive accuracy of cancer therapies. CRISPR-based gene editing integration rose by 44%, improving immune-oncology applications. More than 36% of new oncology CRO developments involved AI-based imaging biomarkers, enabling real-time monitoring of tumor growth. Around 62% of CROs in North America launched new oncology services, while Europe contributed 28% of global oncology product innovations. Asia-Pacific, particularly China, recorded 33% of global oncology CRO product launches. By the end of 2024, over 1,800 new oncology-focused CRO offerings were launched worldwide.

Five Recent Developments

• WuXi AppTec expanded oncology xenograft facilities in China in 2024, increasing capacity by 120,000 studies annually.
• Charles River Laboratory launched CRISPR-engineered oncology animal models in 2024, increasing immune-oncology demand by 38%.
• ICON Plc established a new oncology CRO hub in Ireland in 2023, supporting 80,000 additional studies yearly.
• Eurofins Scientific adopted AI-integrated biomarker testing in 2024, processing 65,000 oncology trials with automated systems.
• Crown Bioscience introduced novel melanoma xenograft models in 2024, supporting 42% higher study accuracy rates.

Report Coverage of Oncology Based In-vivo CRO Market

The Oncology Based In-vivo CRO Market report provides comprehensive coverage across segmentation, regional outlooks, competitive benchmarking, and investment insights. It evaluates over 2,800 CRO service providers globally and tracks more than 18,500 oncology preclinical studies annually. The report examines syngeneic, xenograft, and humanized model usage, representing 86% of CRO testing demand. Applications across blood cancers, solid tumors, and rare cancers are analyzed with factual data from 2023–2024. Regional analysis includes North America, Europe, Asia-Pacific, and Middle East & Africa, covering more than 60 countries. Company profiling includes Eurofins, CRL, WuXi AppTec, ICON, and Covance, which collectively hold over 52% market share. Investment trends highlight over USD 7.5 billion in oncology CRO infrastructure expansion in two years.

Oncology Based In-vivo CRO Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1893.4 Million in 2026
Market Size Value By	USD 3620.97 Million by 2035
Growth Rate	CAGR of 7.47% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Syngeneic Model Xenograft By Application : Blood Cancer Solid Tumors Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample